FUNDAMENTALS · Fundamentals · US Healthcare

Ginkgo Bioworks Holdings (DNA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Ginkgo Bioworks Holdings (DNA) is a US-listed Healthcare company in Biotechnology with a market capitalization of $515M, trading at $7.88 on the NYSE. This SniperIQ fundamentals page covers Ginkgo Bioworks Holdings's valuation, profitability (net margin -215.4%), revenue (

70M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$515M
Net Margin-215.4%
Revenue (FY25)
70M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Ginkgo Bioworks Holdings's market cap?

Ginkgo Bioworks Holdings (DNA) has a market capitalization of approximately $515M, trading at $7.88 on the NYSE. Market cap moves with the live share price.

What is Ginkgo Bioworks Holdings's P/E ratio?

Ginkgo Bioworks Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Ginkgo Bioworks Holdings?

Ginkgo Bioworks Holdings runs a net profit margin of -215.4%, a gross margin of 75.0%, and an operating margin of -210.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Ginkgo Bioworks Holdings generate?

Ginkgo Bioworks Holdings reported revenue of

70M for fiscal year 2025, with net income of -
13M and earnings per share (EPS) of -5.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Ginkgo Bioworks Holdings pay a dividend?

Ginkgo Bioworks Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Ginkgo Bioworks Holdings financially healthy?

Ginkgo Bioworks Holdings carries a debt-to-equity ratio of 0.93x and a current ratio of 5.15x, with a market beta of 1.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Ginkgo Bioworks Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ginkgo Bioworks Holdings (DNA) the key facts are: market cap $515M, revenue

70M, 52-week range 5.37-17.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Ginkgo Bioworks Holdings's full fundamentals live

Get Ginkgo Bioworks Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Relmada Therapeutics (RLMD) fundamentals · Tilray Brands (TLRY) fundamentals · ProKidney (PROK) fundamentals · Nuvectis Pharma (NVCT) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons